COMPANY INFORMATION
Invivoscribe, through its wholly-owned subsidiaries LabPMM, is a leading provider of clinically-validated personalized molecular diagnostics. We provide access to cutting edge testing to physicians and cancer centers world wide, enabling doctors to determine the most successful method of treatment for each patient. The company and its subsidiaries provide one stop comprehensive care for patients in over 50 countries. Invivoscribe's CE-marked IVD products are used to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative diseases. The company's CLIA- and CAP-accredited clinical reference laboratories, LabPMM LLC & LabPMM GmbH, are the only clinical laboratories outside Japan licensed to perform FLT3 biomarker testing, and the only laboratories in the world licensed to determine the mutation status of both FLT3 and NPM1.
PRODUCTS & SERVICES
Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation Research Use Only testing reagents and controls. We also provide CE-marked in vitro diagnostic products to customers outside North America, and our subsidiary, LabPMM, provides comprehensive international access to clinical testing of patient samples. Customers include many of the world's leading pharmaceutical and biotechnology companies, medical centers, cancer research centers, reference laboratories and molecular testing centers.
As a contract research organization, Invivoscribe provides tests and services to assist in the development of pharmaceutical agents and devices. Invivoscribe also produces OEM Reagents dedicated for use with specific analytical platforms.
